HC Wainwright Reiterates “Buy” Rating for Kiora Pharmaceuticals (NASDAQ:KPRX)

Kiora Pharmaceuticals (NASDAQ:KPRX)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research note issued on Tuesday,Benzinga reports. They currently have a $10.00 price objective on the stock. HC Wainwright’s price target suggests a potential upside of 190.70% from the stock’s current price.

Kiora Pharmaceuticals Stock Down 5.0 %

Shares of KPRX stock opened at $3.44 on Tuesday. The stock has a 50-day moving average of $3.53 and a 200-day moving average of $4.28. Kiora Pharmaceuticals has a one year low of $3.00 and a one year high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last announced its quarterly earnings results on Friday, November 8th. The company reported ($0.81) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.90) by $0.09. As a group, research analysts expect that Kiora Pharmaceuticals will post 1.17 EPS for the current year.

Institutional Trading of Kiora Pharmaceuticals

An institutional investor recently bought a new position in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC purchased a new position in shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund purchased 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals comprises about 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th biggest position. Stonepine Capital Management LLC owned about 6.86% of Kiora Pharmaceuticals at the end of the most recent quarter. 76.97% of the stock is currently owned by hedge funds and other institutional investors.

Kiora Pharmaceuticals Company Profile

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.